Dianthus Therapeutics Inc. (DNTH) — Cash Flow Reinvestment Rate
Latest as of September 2023:
7.78x
Dianthus Therapeutics Inc. (DNTH) has a Cash Flow Reinvestment Rate of 7.78x as of September 2023, reinvesting $11.65 Million (capex $145.00K plus investments $-11.51 Million) from operating cash flow of $1.50 Million. See Dianthus Therapeutics Inc. free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
7.78x
(Capex + Investments) / Operating CF
Total Reinvested
$11.65 Million
Capex + Investments
Operating Cash Flow
$1.50 Million
USD
Capital Expenditures
$145.00K
USD
Annual Cash Flow Reinvestment Rate for Dianthus Therapeutics Inc. (None–None)
Year-by-year capital reinvestment analysis for Dianthus Therapeutics Inc.. See Dianthus Therapeutics Inc. (DNTH) financial flexibility to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow